Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human S100A9 Anticorps:
anti-Rat (Rattus) S100A9 Anticorps:
anti-Mouse (Murine) S100A9 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal S100A9 Primary Antibody pour ICC, IF - ABIN409938
Sumi, Shimizu, Himeno: Involvement of Nrf2 activation in the upregulation of S100A9 by exposure to inorganic arsenite. dans International journal of molecular medicine 2012
Show all 6 Pubmed References
Human Monoclonal S100A9 Primary Antibody pour ELISA, WB - ABIN948434
Li, Riau, Setiawan, Mehta, Ti, Tong, Tan, Beuerman: S100A expression in normal corneal-limbal epithelial cells and ocular surface squamous cell carcinoma tissue. dans Molecular vision 2011
Show all 2 Pubmed References
Human Polyclonal S100A9 Primary Antibody pour WB - ABIN519967
Bianchi, Niemiec, Siler, Urban, Reichenbach: Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. dans The Journal of allergy and clinical immunology 2011
Show all 2 Pubmed References
Human Monoclonal S100A9 Primary Antibody pour EIA, FACS - ABIN111888
Brandtzaeg, Jones, Flavell, Fagerhol: Mac 387 antibody and detection of formalin resistant myelomonocytic L1 antigen. dans Journal of clinical pathology 1989
Show all 9 Pubmed References
Human Monoclonal S100A9 Primary Antibody pour EIA, FACS - ABIN111889
Delabie, de Wolf-Peeters, van den Oord, Desmet: Differential expression of the calcium-binding proteins MRP8 and MRP14 in granulomatous conditions: an immunohistochemical study. dans Clinical and experimental immunology 1990
Show all 11 Pubmed References
Human Polyclonal S100A9 Primary Antibody pour IHC (p), IHC - ABIN449656
McCormick, Rahimi, Bobryshev, Gaus, Zreiqat, Cai, Lord, Geczy: S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. dans The Journal of biological chemistry 2005
Show all 2 Pubmed References
Human Monoclonal S100A9 Primary Antibody pour EIA, FACS - ABIN238498
Mortezai, Harder, Schnabel, Moors, Gauly, Schlüter, Wagener, Buck: Tandem affinity depletion: a combination of affinity fractionation and immunoaffinity depletion allows the detection of low-abundance components in the complex proteomes of body fluids. dans Journal of proteome research 2010
Show all 2 Pubmed References
Human Monoclonal S100A9 Primary Antibody pour ELISA, WB - ABIN519968
Feng, Lee, Chang, Chan, Kuo, Lin, Chung, Kuo, Yu, Lin, Wang, Chou, Huang, Kuo: CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. dans American journal of respiratory and critical care medicine 2012
Human Monoclonal S100A9 Primary Antibody pour IA, FACS - ABIN2192037
Robinson, Tessier, Poulsom, Hogg: The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. dans The Journal of biological chemistry 2002
Authors found that downregulation of S100A9 significantly reduced the expression of NF-kappaB (Montrer NFKB1 Anticorps), phosphorylation of NF-kappaB (Montrer NFKB1 Anticorps) and Bcl-2 (Montrer BCL2 Anticorps), as well as the expression of MMP7 (Montrer MMP7 Anticorps) and MMP2 (Montrer MMP2 Anticorps). Restoration of NF-kappaB (Montrer NFKB1 Anticorps) expression sufficiently reversed the inhibitory effects on cell proliferation and invasion induced by S100A9 downregulation in vitro and in vivo.
Urinary NGAL (Montrer LCN2 Anticorps) is a good predictor of mortality in established pediatric acute kidney injury (AKI) of heterogeneous etiology and outperforms calprotectin (Montrer S100A8 Anticorps) and KIM-1 (Montrer HAVCR1 Anticorps). Urinary calprotectin (Montrer S100A8 Anticorps) and KIM-1 (Montrer HAVCR1 Anticorps) predict renal replacement therapy requirement in pediatric AKI.
Identify proteins that interact with calgranulin B to suppress the proliferation of colon cancer cells.
This study demonstrated that S100A9 was detected in the serums of Alzheimer disease patients
Expression levels of S100A9 and Tenascin-C (Montrer TNC Anticorps) were correlated with TNM (Montrer ODZ1 Anticorps) stages and metastasis in colorectal cancer.
In Guatemalan preschoolers, the median fecal calprotectin (Montrer S100A8 Anticorps) value was 58 mg/kg, with a mean of 98 +/- 136 mg/kg and a range from 10 to 950 mg/kg; 61% of values were above the manufacturer's cut-off for elevated concentration and 51% exceeded an age-adjusted criterion. The central tendency (mean or median) and distribution were generally shifted to the right in relation to comparable reports from children across the world.
Low S100A9 expression is associated with head and neck neoplasms.
Report role of fecal calprotectin (Montrer S100A8 Anticorps) assay in the diagnosis and management of inflammatory bowel disease.
S100A8 (Montrer S100A8 Anticorps) and S100A9 aggravate Coxsackievirus B3-induced myocarditis and might serve as therapeutic targets in inflammatory cardiomyopathies.
Calprotectin (Montrer S100A8 Anticorps) had the highest association with ultrasound synovitis and predicted treatment response. It may thus be considered as a marker for evaluating inflammation and responsiveness in patients with rheumatoid arthritis on biologic disease-modifying anti-rheumatic drug treatment.
Data suggest that up-regulation of S100A8 (Montrer S100A8 Anticorps) and S100A9 is a key component of early endometrial response to uterine involution in the post-partum period and to prevent chronic endometritis/uterine inflammation; up-regulation can be influenced by diet.
Study verified porcine calprotectin (S100A8 (Montrer S100A8 Anticorps)/A9) expression at the protein level in multiple Haemophilus parasuis infected tissues and explored their molecular characterization.
this study shows that S100A9 inhibits B lymphopoiesis by acting on myeloid cells and promoting the release of inflammatory molecules, including IL-1beta (Montrer IL1B Anticorps)
Like S100A8 (Montrer S100A8 Anticorps), S100A9 and S100A8 (Montrer S100A8 Anticorps)/A9 reduced neutrophil influx in acute lung injury provoked by lipopolysaccharide (LPS (Montrer TLR4 Anticorps)) challenge.
findings reveal unexpected gene expression differences between WT and KO mice at a young age (in the absence of physiological stress), and address the hypothesis that Mrp8 (Montrer S100A8 Anticorps) and Mrp14 accumulation promotes age-related inflammation
An excessive expansion of monocytic-myeloid-derived suppressor cells in S100A9-/- neonates compared to wild-type neonates. This strong baseline expansion was associated with hyperinflammatory responses during endotoxemia and fatal septic courses
Data support a role of S100A9 to initiate and amplify the neutrophilic inflammation in asthma, possibly via inducing IL-1beta (Montrer IL1B Anticorps), IL-17 (Montrer IL17A Anticorps) and IFN-gamma (Montrer IFNG Anticorps).
The findings show that reduced PTP1B (Montrer PTPN1 Anticorps) responses contribute to disease symptoms in part by enhancing S100A9 expression during viral-associated chronic obstructive pulmonary disease exacerbations.
Neutrophil-derived S100A8 (Montrer S100A8 Anticorps)/A9 promotes thrombocytosis in diabetic mice
S100A9 knockdown almost completely abrogated the effects of IRF7 (Montrer IRF7 Anticorps) deletion on granulocytic myeloid-derived suppressor cells development and tumor metastasis.
Perinatal alarmins S100A8 (Montrer S100A8 Anticorps) and S100A9 specifically altered MyD88 (Montrer MYD88 Anticorps)-dependent proinflammatory gene programs. S100 programming prevented hyperinflammatory responses without impairing pathogen defense. TRIF (Montrer RNF138 Anticorps)-adaptor-dependent regulatory genes remained unaffected by perinatal S100 programming and responded strongly to lipopolysaccharide, but were barely expressed.
vitro studies on the mechanisms/pathways involved in leukemic cell differentiation revealed that binding of S100A9 to Toll-like receptor 4 (TLR4 (Montrer TLR4 Anticorps)) promotes activation of p38 mitogen-activated protein kinase (Montrer MAPK14 Anticorps), extracellular signal-regulated kinases 1 and 2, and Jun N-terminal kinase (Montrer MAPK8 Anticorps) signaling pathways, leading to myelomonocytic and monocytic AML (Montrer RUNX1 Anticorps) cell differentiation.
Calprotectin (Montrer S100A8 Anticorps) expression in laminar epidermis occurs after extravasation of leukocytes indicating that leukocyte emigration may be an initiating factor in laminar epithelial stress and inflammation in black walnut extract-induced laminitis.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein may function in the inhibition of casein kinase and altered expression of this protein is associated with the disease cystic fibrosis.
, S100 calcium-binding protein A9 (calgranulin B)
, calgranulin B
, calprotectin L1H subunit
, leukocyte L1 complex heavy chain
, migration inhibitory factor-related protein 14
, protein S100-A9
, S100 calcium binding protein A9 (calgranulin B)
, intracellular calcium-binding protein (MRP14)
, myeloid-related protein 14
, protein MRP-126
, S100 calcium binding protein A9
, S100 calcium-binding protein A9
, neutrophil cytosolic 23 kDa protein
, RNA-binding region containing protein 2-like